Genenta Science SPA (Genenta Science SPA) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Genenta Science SPA Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Genenta Science SPA's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Genenta Science SPA could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Genenta Science SPA's Cash-to-Debt or its related term are showing as below:

GNTA' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 5 years, Genenta Science SPA's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

GNTA's Cash-to-Debt is ranked better than
99.8% of 1493 companies
in the Biotechnology industry
Industry Median: 6.89 vs GNTA: No Debt

Genenta Science SPA Cash-to-Debt Historical Data

The historical data trend for Genenta Science SPA's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Genenta Science SPA Cash-to-Debt Chart

Genenta Science SPA Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

No Debt

Genenta Science SPA Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial				No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Genenta Science SPA's Cash-to-Debt

For the Biotechnology subindustry, Genenta Science SPA's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genenta Science SPA's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genenta Science SPA's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Genenta Science SPA's Cash-to-Debt falls into.

Genenta Science SPA Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Genenta Science SPA's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Genenta Science SPA had no debt ⁽¹⁾.

Genenta Science SPA's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Genenta Science SPA had no debt ⁽¹⁾.

Genenta Science SPA (NAS:GNTA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Genenta Science SPA Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Genenta Science SPA's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Genenta Science SPA (Genenta Science SPA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genenta Science SPA (NAS:GNTA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

K5F:Germany

Address

Via Olgettina No. 58, Milan, ITA, 20132

Website

https://www.genenta.com

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's lead product includes Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.